GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. - United Kingdom 

Ranking results:

Past rankings:

2020
Criterium:Position:
Overall Score:> 1000
Total Number of Projects:900-1000
2019
Criterium:Position:
Overall Score:400-500
Total Project Funding per Partner:> 1000
Total Number of Projects:300-400
2018
Criterium:Position:
Overall Score:> 1000
Total Number of Projects:500-600
Networking Rank (Reputation):> 1000
2016
Criterium:Position:
Overall Score:600-700
Networking Rank (Reputation):300-400
2015
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
Networking Rank (Reputation):> 1000
2011
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:800-900
Total Number of Projects:> 1000
Total Project Funding:900-1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2010
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2009
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000
2008
Criterium:Position:
Overall Score:900-1000
Total Project Funding per Partner:600-700
Total Number of Projects:700-800
Total Project Funding:800-900
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:600-700
2007
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:> 1000
Project Leadership Index:> 1000
Diversity Index:> 1000

Ranking timeline:

Project Participation Performance(2010-01-01 - 2024-12-31 ):

Total Project Funding:

Funding per Partner:

Projects:

Leadership:

Total number of projects: 36
As coordinator: 0
As participant: 36
Sole participant: 0
Coordinator / Participant Ratio: 0*

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2020 0 34.339.748 0 4
2019 0 113.210.219 606.345 10
2018 0 81.343.241 0 6
2017 0 41.375.516 323.750 6
2016 0 100.045.313 77.281 4
2015 0 24.408.946 773.288 3
2012 0 3.935.114 280.861 1
2011 0 11.982.403 9.000 1
2010 0 2.912.936 659.502 1

Networking:

Partners:

Institution:Projects [No]:
NOVARTIS PHARMA15
JANSSEN PHARMACEUTICA NV12
PFIZER LIMITED11
BAYER10
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE10
SANOFIAVENTIS10
ELI LILLY AND COMPANY LIMITED9
KATHOLIEKE UNIVERSITEIT LEUVEN9
UCB BIOPHARMA9
NOVO NORDISK8
F HOFFMANNLA ROCHE7
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD7
ASTRAZENECA6
KAROLINSKA INSTITUTE6
ACADEMISCH ZIEKENHUIS GRONINGEN5
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG5
FORUM DES PATIENTS EUROPEENS5
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER IRIS5
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN5
MERCK SHARP & DOHME CORP5
STICHTING KATHOLIEKE UNIVERSITEIT5
THE UNIVERSITY OF MANCHESTER5
UNIVERSITY OF COPENHAGEN5
ABBVIE INC4
BRISTOLMYERS SQUIBB COMPANY CORP4
EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE4
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V4
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE4
KING'S COLLEGE LONDON4
UNIVERSITAIR MEDISCH CENTRUM UTRECHT4
VTT TECHNICAL RESEARCH CENTRE OF FINLAND4
ACADEMISCH ZIEKENHUIS LEIDEN3
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE3
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS3
DANMARKS TEKNISKE UNIVERSITET3
ELI LILLY AND COMPANY3
EUROPEAN MOLECULAR BIOLOGY LABORATORY3
FUNDACIO INSTITUT DE CIENCIES FOTONIQUES3
OSPEDALE PEDIATRICO BAMBINO GESU3
QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON3
REGION HOVEDSTADEN3
RIJKSUNIVERSITEIT GRONINGEN3
SANOFIAVENTIS DEUTSCHLAND3
STICHTING RADBOUD UNIVERSITEIT3
TAKEDA DEVELOPMENT CENTRE EUROPE3
TAKEDA PHARMACEUTICALS INTERNATIONAL3
TARTU ULIKOOL3
TECHNISCHE UNIVERSITAET DRESDEN3
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE3
THE UNIVERSITY OF LIVERPOOL3
UNIVERSITA DEGLI STUDI DI PISA3
UNIVERSITA DEGLI STUDI DI SIENA3
UNIVERSITAET ULM3
UNIVERSITE DE GENEVE3
UNIVERSITE DU LUXEMBOURG3
UNIVERSITE LIBRE DE BRUXELLES3
UNIVERSITEIT GENT3
UNIVERSITEIT MAASTRICHT3
UNIVERSITY COLLEGE LONDON3
UNIVERSITY OF BIRMINGHAM3
UNIVERSITY OF CAMBRIDGE3
UNIVERSITY OF LEEDS3
UNIVERSITY OF NEWCASTLE UPON TYNE3
UPPSALA UNIVERSITET3
ABBVIE DEUTSCHLAND GMBH & CO KG2
ACADEMIC MEDICAL CENTRE AMSTERDAM2
AMGEN LIMITED2
ASTELLAS PHARMA EUROPE BV2
ASTRAZENECA AB2
BEACTICA THERAPEUTICS AB2
CENTRE DE REGULACIO GENOMICA2
CENTRE HOSPITALIER DE LUXEMBOURG2
CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE NANCY2
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS2
CHALMERS TEKNISKA HOEGSKOLA AB2
CHARITE UNIVERSITAETSMEDIZIN BERLIN2
CHRISTIAN ALBRECHTS UNIVERSITAET ZU KIEL2
COMMISSARIAT A L'ENERGIE ATOMIQUE2
CONSIGLIO NAZIONALE DELLE RICERCHE2
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER2
COVANCE LABORATORIES2
DEUTSCHES RHEUMAFORSCHUNGSZENTRUM BERLIN2
DRESDEN UNIVERSITY OF TECHNOLOGY2
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE2
ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK2
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH2
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE2
EUROPEAN AIDS TREATMENT GROUP EV2
EUROPEAN FEDERATION OF ASTHMA &ALLERGY ASSOCIATIONS IDEELL FORENING2
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL2
EURORDIS EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION2
FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES2
FUNDACIO INSTITUT MAR D INVESTIGACIONS MEDIQUES IMIM2
FUNDACIO SANT JOAN DE DEU2
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD2
HANNOVERSCHE KINDERHEILANSTALT2
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER2
INSTITUT DE RECHERCHES SERVIER2
INTERUNIVERSITAIR MICRO ELECTRONICA CENTRUM VZW2
JDRF INTERNATIONAL2

Constancy:

Total number of partners: 942
Partner loyalty:
Frequent Partner: (> 2 projects): 305
Rare Partner: 637
Frequent / Rare Partner Ratio: 0.48

Project overview:

Start dateProjectacronymrolefundingpartners
2020-09-01Prioritisation and Risk Evaluation of Medicines in the EnviRonment PREMIERparticipant4.550.00025
2020-05-01Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA INNODIA HARVESTparticipant5.999.05541
2020-01-01PharmaLedger PharmaLedgerparticipant8.290.69430
2020-01-01Better control and treatment of immune-mediated diseases by exploring the universe of microenvironment imposed tissue signatures and their correlates in liquid biopsies ImmUniverseparticipant15.500.00028
2019-12-01Short linear interaction motifs as specificity determinants in the ubiquitin system – discovery, mechanisms and therapeutic opportunities UBIMOTIFparticipant4.147.22311
2019-11-01Collaboration for Prevention and Treatment of MDR Bacterial Infections COMBINEparticipant8.000.00011
2019-09-01Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions 3TRparticipant40.273.19270
2019-07-01Antibiotic Distribution and Recovery in Tissue AB-DiRecTparticipant3.429.2176
2019-06-01MachinE Learning Ledger Orchestration for Drug DiscoverY MELLODDYparticipant8.000.00017
2019-04-01Multiphoton Microscopy and Ultrafast Spectroscopy: Imaging meets Quantum MUSIQparticipant4.034.44716
2019-04-01Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation ConcePTIONparticipant15.299.99153
2019-03-01Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts IMMUcanparticipant17.830.00028
2019-01-01NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients NECESSITYparticipant8.200.00025
2019-01-01FAIRplus FAIRplusparticipant3.996.15022
2018-09-01Ensuring the future of EUPATI beyond 2020 EFOEUPATIparticipant365.24312
2018-06-01The GetReal Initiative GetReal Initiativeparticipant1.750.00017
2018-05-01Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production iConsensusparticipant4.700.00019
2018-05-01conect4children (COllaborative Network for European Clinical Trials For Children) c4cparticipant67.000.00047
2018-03-01Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. PARADIGMparticipant4.498.93135
2018-01-01Light-driven sustainable biocatalysis training network PhotoBioCatparticipant3.029.06719
2017-09-01Rheuma Tolerance for Cure RTCureparticipant6.000.00020
2017-03-01Directed Protein Evolution for Synthetic Biology and Biocatalysis ES-Catparticipant3.827.03119
2017-02-01Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 DO-ITparticipant3.549.83336
2017-01-01Translational quantitative systems toxicology to improve the understanding of the safety of medicines - Sofia: 116030 TransQSTparticipant8.000.00023
2017-01-01INternational Smart Collaborative Open-access hybrid Printed Electronics pilot line InSCOPEparticipant7.998.65211
2017-01-01Imaging Biomarkers (IBs) for Safer Drugs: Validation of Translational Imaging Methods in Drug Safety Assessment - Sofia ref.: 116106 IB4SD-TRISTANparticipant12.000.00021
2016-04-01Graphene-based disruptive technologies GrapheneCore1participant89.000.000186
2016-03-01FRAGments training NETwork FRAGNETparticipant3.842.48213
2016-03-01New Diagnostics for Infectious Diseases: “ND4ID” ND4IDparticipant3.860.50823
2016-02-01Targeted small-molecule Stabilisation of Protein-Protein Interactions TASPPIparticipant3.342.32312
2015-11-01Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes – Sofia ref.: 115797 INNODIAparticipant17.630.00036
2015-01-01The next generation epigenetic medicine for inflammation EPIMACparticipant1.294.7852
2015-01-01Robust and affordable process control technologies for improving standards and optimising industrial operations ProPATparticipant5.484.16117
2012-01-01Novel Statistical Methodology for Diagnostic/Prognostic and Therapeutic Studies and Systematic Reviews MEDIASRESparticipant3.935.11410
2011-12-01Developing a global understanding of the PRC and NuRD complexes in stem cell differentiation, in health and disease 4DCELLFATEparticipant11.982.40313
2010-01-01Methods in Neuroimaging NeuroPhysicsparticipant2.912.9364

Alias institution names:

  • GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT